Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Clinical trial NCT04607668 · TERMINATED
Trial details
- NCT number
- NCT04607668
- Sponsor
- G1 Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-06
- Primary completion
- 2023-02-13
- Enrollment
- 326
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.